Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29552438 | 1.00 | MAPK1 (0.65) | MAPK1L3MBTL1KDM4ENAPRTSMN1; SMN2 | |
| SCHEMBL29776105 | 0.98 | MAPK1 (0.62) | MAPK1L3MBTL1KDM4ENAPRTSMN1; SMN2 | |
| SCHEMBL20241211 | 0.98 | MAPK1 (0.62) | MAPK1L3MBTL1KDM4ENAPRTSMN1; SMN2 | |
| SCHEMBL23796888 | 0.87 | NAPRT (0.55) | MAPK1L3MBTL1KDM4ENAPRTSMN1; SMN2 | |
| SCHEMBL2651925 | 0.86 | MAPK1 (0.50) | MAPK1L3MBTL1KDM4ENAPRTSMN1; SMN2 | |
| SCHEMBL2952147 | 0.86 | KDM4E (0.50) | MAPK1L3MBTL1KDM4ENAPRTSMN1; SMN2 | |
| SCHEMBL38659193 | 0.86 | KDM4E (0.50) | MAPK1L3MBTL1KDM4ENAPRTSMN1; SMN2 | |
| SCHEMBL5867481 | 0.85 | L3MBTL1 (0.50) | MAPK1L3MBTL1KDM4ENAPRTSMN1; SMN2 | |
| SCHEMBL2302748 | 0.84 | RAB9A (0.74) | L3MBTL1SMN1; SMN2RAB9AMAPTMEN1 | |
| SCHEMBL6208353 | 0.84 | MAPK1 (0.48) | MAPK1L3MBTL1KDM4ENAPRTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1809 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119592966-A | Method for synthesizing ester compounds by high-selectivity dechlorination electro-catalysis | 浙江工业大学 | 2025-03-11 | — | — | CN | claimed |
| EP-3675845-B1 | NOVEL GAMMA AMINOBUTYRIC ACID TYPE A RECEPTOR MODULATORS FOR MOOD DISORDERS | UNIV MARYLAND (US) | 2024-07-17 | — | — | EP | claimed |
| CN-113649055-B | Catalyst for selective hydrogenation of methyl picolinate and preparation method and application thereof | 湖北大学 | 2023-03-24 | — | — | CN | claimed |
| US-20220396572-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-12-15 | — | — | US | claimed |
| US-11459320-B2 | Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type A receptors as fast acting treatment for depression and mood disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-10-04 | — | — | US | claimed |
| CN-114149425-A | 5-fluoromethylpyridine derivative and 18-F isotope labeled 5-fluoromethylpyridine derivative, and preparation and application thereof | 上海应用技术大学 | 2022-03-08 | — | — | CN | claimed |
| CN-113649055-A | Catalyst for selective hydrogenation of methyl picolinate and preparation method and application thereof | 湖北大学 | 2021-11-16 | — | — | CN | claimed |
| WO-2019046300-A9 | NOVEL GAMMA AMINOBUTYRIC ACID TYPE A RECEPTOR MODULATORS FOR MOOD DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-10-15 | — | — | WO | claimed |
| EP-3675845-A1 | NOVEL GAMMA AMINOBUTYRIC ACID TYPE A RECEPTOR MODULATORS FOR MOOD DISORDERS | University of Maryland, Baltimore (US) | 2020-07-08 | — | — | EP | claimed |
| US-20200199119-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-25 | — | — | US | claimed |
| WO-2019046300-A1 | NOVEL GAMMA AMINOBUTYRIC ACID TYPE A RECEPTOR MODULATORS FOR MOOD DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2019-03-07 | — | — | WO | claimed |
| EP-2227467-B1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | claimed |
| EP-2227467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | claimed |
| WO-2009071476-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | claimed |
| US-20060058248-A1 | Processes for the preparation of 6-11 bicyclic erythromycin derivatives | XU GUOYOU | 2006-03-16 | — | — | US | claimed |
| WO-2005070918-A1 | PROCESS FOR THE PREPARATION OF T-11 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | claimed |
| US-20040171818-A1 | Processes for the preparation of 6-11 bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | claimed |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | LG CHEM, LTD. (KR) | 2026-05-26 | — | — | US | disclosed |
| EP-0013153-A1 | 6-Amino pyridine carboxylic acid derivatives, a process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1980-07-09 | — | — | EP | disclosed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199119-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | GABRA5, GABRA4, GABRA1 | MAPK1 3972/4885L3MBTL1 2181/4885KDM4E 1067/4885 |
| US-20060058248-A1 | Processes for the preparation of 6-11 bicyclic erythromycin derivatives | CYP2B6, CYP2D6, CYP2C9 | MAPK1 1788/4885L3MBTL1 4749/4885KDM4E 1590/4885 |
| US-20040171818-A1 | Processes for the preparation of 6-11 bicyclic erythromycin derivatives | CYP2B6, CYP7A1, CYP2D6 | MAPK1 1321/4885L3MBTL1 4723/4885KDM4E 1709/4885 |
| US-11459320-B2 | Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type A receptors as fast acting treatment for depression and mood disorders | GABRA5, GABRA4, GABRA1 | MAPK1 3972/4885L3MBTL1 2181/4885KDM4E 1067/4885 |
| US-20220396572-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | GABRA5, GABRA4, GABRA1 | MAPK1 3972/4885L3MBTL1 2181/4885KDM4E 1067/4885 |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | DGAT2, DGAT1, DLAT | MAPK1 2480/4885L3MBTL1 991/4885KDM4E 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.